MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors
MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors FDA-registered Section 506(e) outsourcing facility and U.S. CDMO offers audit-ready sterile injectable biologics and Rx/OTC oral solid dosage manufacturing to strengthen domestic federal medical supply chains. DALLAS, TX — November 2026 — MayMag Biologics Corp (formerly Tirzepatide Pharma), an FDA-registered Section 506(e) outsourcing facility and U. S. -based Contract Development and Manufacturing Organization (CDMO), announced today the expansion of its domestic co-manufacturing and fill-finish partnerships tailored specifically for SAM. gov prime contract awardees. Operating dual cGMP-certified manufacturing facilities in Dallas and Garland, Texas, MayMag Biologics provides federal prime contractors with a compliant, onshore partner for sterile injectable biologics and prescription (Rx) and over-the-counter (OTC) oral solid dosages. As federal age...